Compare Endeavour Silver Corp (EXK) vs Cassava Sciences Inc (FLNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Endeavour Silver Corp vs Cassava Sciences Inc — how do they compare? Endeavour Silver Corp trades at $8.86 (market cap $2.46B), while Cassava Sciences Inc trades at $0.82 (market cap $39.40M). The key difference: Endeavour Silver Corp is far larger — about 62.4× Cassava Sciences Inc's market cap, and Endeavour Silver Corp is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Endeavour Silver Corp for 25 Days and Cassava Sciences Inc for 37 Days on average.
| EXK | FLNA | |
|---|---|---|
Market Cap | $2.46B | $39.40M |
Volume | 5,827,665 | 759,018 |
Sector | Basic Materials | Health |
52-Week High | $14.12 | $4.64 |
52-Week Low | $7.07 | $0.68 |
Typical Hold Time | 25 Days | 37 Days |
Enterprise Value | $2.47B | -$43.28M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Endeavour Silver (EXK) trades at $8.32, down 4.04% on the day, amid a bearish technical signal. The company reported a net loss of $119.1M in 2025 but expects a significant turnaround in 2026 with projected net income of $66M. Recent news highlights operational progress at the Terronera and Kolpa mines, though temporary disruptions have occurred. Analyst consensus is strongly bullish with a $10.50 price target, but technical indicators show selling pressure.
The outlook is mixed: strong analyst support and projected profitability in 2026 present upside, but near-term technical weakness and operational risks like mine blockades pose challenges. The stock's valuation multiples are elevated relative to current earnings, requiring successful execution of growth plans to justify further gains.
FLNA trades at $0.8136, down 7.01% today, with a bearish technical signal from moving averages. The company shows negative profitability with ROE at -55.79% and ROA at -35.34%, though it has beaten EPS estimates for three consecutive quarters. Recent FDA approval to lift the clinical hold on simufilam for epilepsy research provides a positive catalyst, with patient screening expected by Q1 2027.
Despite operational losses and negative cash flow, analyst consensus is bullish with 8 buy ratings versus 4 hold. The key investment opportunity lies in the clinical progress of simufilam, while risks include sustained cash burn and reliance on successful drug development outcomes in a competitive biotech landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Endeavour Silver Corp
Endeavour Silver is a mid-tier precious metals mining company. It operates silver-gold mines in Mexico and is focused on growing its production and reserves through exploration and the development of new mining projects.
Read more on EXK →About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →
